🔬Beyond AlphaFold: How Boltz is Open-Sourcing the Future of Drug Discovery

Boltz, co-founded by Gabriele Corso and Jeremy Wohlwend, aims to democratize structural prediction in biology. The discussion centers on the transformative impact of AlphaFold and AlphaFold 3 on protein structure prediction and the challenges of modeling protein interactions. CASP competitions are highlighted as benchmarks for model generalization, particularly in predicting single-chain protein structures using evolutionary data. The conversation explores the shift from regression to generative modeling for dynamic systems and uncertainty handling, as well as the architectural and data changes enabling AlphaFold 3's advancements. Boltz Lab, the company's platform, integrates agents, infrastructure, and user interfaces to facilitate efficient design campaigns and collaboration among medicinal chemists.